LGND Ligand Pharmaceuticals Inc - Class B Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: LGND
  4. Earnings
?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 87
Relative Valuation: Rel. Valuation: 56
Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $10.07

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the current EPS (TTM) is $10.07. Ligand Pharmaceuticals Inc - Class B's EPS for 2025 came in at $6.44, marking an increase from -$0.22 in 2024. For the quarterly period ending on Jun 30, 2026, LGND's EPS was $2.42.

LGND earnings history

Historical annual and quarterly earnings per share (EPS) data for Ligand Pharmaceuticals Inc - Class B
EPS (TTM)
$10.07
EPS Growth YoY (Quarterly)
868%
EPS (Quarterly)
$2.42
EPS Growth (Quarterly)
461.2%

Ligand Pharmaceuticals Inc - Class B had an annual EPS of $6.44, marking an increase of 3,027.3% from -$0.22 in 2024. The quarterly EPS for the period ending Jun 30, 2026, was $2.42, marking a 868% increase from the same quarter last year. LGND's TTM EPS stands at $10.07 as of June 2026. Ligand Pharmaceuticals Inc - Class B's EPS for 2024 stood at -$0.22, a 107.3% decrease from 2023.

LGND EPS vs price chart

LGND EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
868%
EPS growth YoY
3,027.3%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Ligand Pharmaceuticals Inc - Class B has recorded an increase in EPS of 868% over the last 12 months (YoY, quarterly). Across the last decade, LGND had an average annual EPS growth of -5.7%.

LGND Earnings Waterfall

Breakdown of revenue, profit and net income for Ligand Pharmaceuticals Inc - Class B

LGND Earnings vs Peers

What are the earnings of LGND compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol-Myers Squibb Company 14.73 178.7% 5.3% N/A
AMGN AMGEN Inc 27.09 88.1% 5.6% 2.9%
LGND Ligand Pharmaceuticals Inc - Class B 28.43 3,027.3% N/A N/A
JNJ Johnson & Johnson 30.96 90.6% 17.7% 14.8%
PFE Pfizer Inc 36.93 -3.5% -37.4% -3.7%
LLY Lilly(Eli) & Company 42.07 95.6% 49.2% 27.5%
MRK Merck & Co Inc 120.12 8% 8.4% 21.2%
BAX Baxter International Inc N/A -47.2% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.